HLS Therapeutics (HLS Therapeutics) ROCE %

: -5.83% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HLS Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -5.83%.

HLS Therapeutics ROCE % Historical Data

The historical data trend for HLS Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-4.72

-3.70

-1.88

-7.15

-9.70

HLS Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																-8.52	-7.57	-14.82	-10.45	-5.83

HLS Therapeutics ROCE % Calculation

HLS Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.055	/	( ( (241.652 - 31.19)	+	(209.06 - 26.688) )	/ 2 )
	=	-19.055	/	( (210.462	+	182.372)	/ 2 )
	=	-19.055	/	196.417
	=	-9.70 %

HLS Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-10.852	/	( ( (215.228 - 25.303)	+	(209.06 - 26.688) )	/ 2 )
	=	-10.852	/	( ( 189.925	+	182.372 )	/ 2 )
	=	-10.852	/	186.1485
	=	-5.83 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

HLS Therapeutics (OTCPK:HLTRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HLS Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (HLS Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA • 03-21-2013